1 / 27

Blending Research and Practice: The Clinical Trials Network and Beyond

Blending Research and Practice: The Clinical Trials Network and Beyond. Dennis McCarty, PhD Oregon Health & Science University Oregon/Hawaii Node of the Clinical Trials Network. 1998 IOM Report. IOM (1998): Recommendation 1.

susane
Download Presentation

Blending Research and Practice: The Clinical Trials Network and Beyond

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Blending Research and Practice: The Clinical Trials Network and Beyond Dennis McCarty, PhD Oregon Health & Science University Oregon/Hawaii Node of the Clinical Trials Network

  2. 1998 IOM Report

  3. IOM (1998): Recommendation 1 • The National Institute on Drug Abuse and the Center for Substance Abuse Treatment should support the development of an infrastructure to facilitate research within a network of community-based treatment programs, similar to the National Cancer Institute’s Community Clinical Oncology Program (CCOP) networks.

  4. National Drug Abuse Treatment Clinical Trials Network • 17 Regional Research and Training Centers • Over 200 drug abuse treatment programs • Conducting randomized clinical trials of emerging pharmacological and behavioral therapies • 18 completed trials • Over 7,000 study participants

  5. Trials of Pharmacological Therapies • Buprenorphine (Suboxone) • Bup/Nx vs Clonidine • Bup/Nx vs Methadone • Bup/Nx for adolescents • Bup/Nx for prescription opiate dependence • Osmotic-Release Methylphenidate (Concerta) • Adult smokers • Adolescents • Nicotine replacement in drug treatment

  6. Results: Buprenorphine/Naloxone • Can be use safely and effectively in community treatment settings (Amass et al, 2004) • More patients stay in care and complete care with buprenorphine (Ling et al, 2005) • 7 day taper is as effective as a 30 day taper (Ling et al, under review) • Programs continue to use • Maryhaven, Columbus OH (Brigham et al, in press) • Phoenix House, NY, NY (Collins et al, in press) • Kaiser-Permanente NW, Portland, OR • 100+ maintenance patients

  7. Trials of Behavioral Therapies • Lower cost motivational incentives • Motivational interviewing & enhancement therapy • Adults; pregnant women; Spanish speakers • Seeking Safety – trauma counseling for women • Reducing HIV/HCV risk behavior • Injection drug use; sex risks for women & men • Job Seekers vocational training • Brief Strategic Family Therapy • Counselor feedback • Telephone Enhancement to Improve Aftercare

  8. Results: Motivational Incentives • Methadone patients reduce use of cocaine (Pierce et al, 2005) • Outpatients improve retention in care (Petry et al, 2005) • Lower cost incentives are effective • Motivational Incentives are cost-effective (Olmstead, Sindelar & Petry, in press)

  9. Results: Motivational Interviewing • Motivational interviewing increased retention in care (Carroll, et al, 2006) • Effective for alcohol and drug dependent patients

  10. Benefits to Participating Treatment Centers • Exposure to emerging therapies • Staff training • Participation in research • CTN trials • Additional investigations • More competitive in service awards from CSAT, HRSA, RWJF, etc

  11. Examples from the Oregon/Hawaii Node • Adapt (Roseburg, OR) • HRSA Rural Health Outreach Program to integrate behavioral health care in a health clinic • State award to apply community reinforcement therapy to work with problem gamblers • ChangePoint (Portland, OR) • CSAT award to implement Matrix methamphetamine treatment model

  12. Examples from the Oregon/Hawaii Node (continued) • CODA (Portland, OR) • RWJF award to participate in the Network for the Improvement of Addiction Treatment • HRSA demonstration to integrate buprenorphine into HIV primary care • Kaiser Permanente (Portland, OR) • NIDA award to study adoption of buprenorphine • NIMH award to study recovery from serious mental illness

  13. Examples from the Oregon/Hawaii Node (continued) • Native American Rehabilitation Association • CSAT award to treat methamphetamine use • CDC award to reduce tobacco use • New Directions Northwest (Baker City, OR) • Participates in CJ-DATS • Oregon Practice Improvement Collaborative • Willamette Family (Eugene, OR) • CSAT award for treating adolescent women • CMHS award to integrate care for adolescent women

  14. Who participates in the CTN? (McCarty et al, Psychiatric Services, 2007) • CTN-0008 Baseline Protocol Surveyed • Organizations: 106 of 112 (95%) • Treatment Units: 348 of 384 (91%) • Workforce: 3,786 of 5,334 (71%) • 1,757 counselors • 533 managers and supervisors • 511 medical staff • 908 support staff(88 missing data)

  15. Types of Corporations in the CTN (vs the National Survey of Substance Abuse Treatment Services)

  16. Primary Service Setting for CTN members(versus the 2003 N-SSATS)

  17. Attitudes toward use of confrontation and noncompliance discharge by job category (-2 = strongly disagree; +2 = strongly agree)

  18. Attitudes toward use of incentives by job category (-2 = strongly disagree; +2 = strongly agree)

  19. Attitudes toward use of medications by job category (-2 = strongly disagree; +2 = strongly agree)

  20. Adoption in CTN versus other treatment programs • CTN programs 5 times more likely to use buprenorphine when organizational factors controlled statistically • Treatment programs in bup trials = 46% • Other CTN treatment programs = 16% • Treatment programs not in CTN = 11%Ducharme, L. J., Knudsen, H. K., Roman, P. M., & Johnson, J. A. (In press). Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network. Journal of Substance Abuse Treatment. • Buprenorphine more acceptable to CTN counselors Knudsen, H. K., Ducharme, L. J., & Roman, P. M. (In press). Research network involvement and addiction treatment center staff: Counselor attitudes toward buprenorphine. The American Journal on Addictions.

  21. Blending Initiative • SAMHSA-NIDA Collaboration through ATTCs • Blending products: • Buprenorphine Treatment: A Training • Short-Term Opioid Withdrawal Using Buprenorphine: Findings and strategies • SMART Treatment Planning: Utilizing the ASI • MI Assessment: Supervisory Tools for Enhancing Proficiency • Promoting Awareness of Motivational Incentives

  22. MI Assessment: Supervisory Tools for Enhancing Proficiency (MIA: STEP) • Clinical trials and MI • Known effects on engagement and retention in controlled studies • Established efficacy in reducing substance use among alcohol and drug using clients • Need to test MI effectiveness in community agencies • Blending Team objectives and assumptions • Develop a package that promotes the use of MI • Provide tools useful to community providers • Field does not need another MI training package • MI skills erode quickly without feedback and coaching following training

  23. MIA: STEP Blending Product • A tool kit for enhancing clinical proficiency in using MI • A resource for supervisors who mentor clinicians • A multi-media package of products for enhancing individual and group learning • A set of materials in the public domain that can be copied and customized to meet specific needs

  24. MIA:STEP Overview • Briefing materials • Summary of the MI Assessment intervention • Results of the NIDA CTN Research • Teaching tools for enhancing and assessing MI skills • Interview rating guide and demonstration materials • Supervisor training curriculum

  25. MIA:STEP The MIA:STEP package is available in several forms: • Downloadable and editable version is at: www.nfattc.org • Downloadable published pdf version • Print version plus CDs of tools and demonstration interviews available from Northwest Frontier ATTC • CD package alone available from the Mid-Atlantic ATTC

  26. Concluding Comments Persistent improvements in the quality and effectiveness of care

  27. Acknowledgements • Preparation of this presentation was supported through awards from • The National Institute on Drug Abuse: R01 DA018282 • The National Institute on Drug Abuse: R01 DA020832 • The National Institute on Drug Abuse: U10 DA013036 • Robert Wood Johnson Foundation: 46876 & 50165 • The Center for Substance Abuse Treatment: SAMHSA SC-05-110

More Related